A study by Mellergård et al. (2010) suggested there was a marked decline in CSF levels of cytokines and chemokines in MS patients treated with natalizumab, thus concluding chemokines associated with both Th1 (CXCL9, CXCL10, CXCL11) and Th2 (CCL22). The gene discussed is CXCL11; the disease is myeloid sarcoma.